News-Che Tou Pharmaceutical-Pharmaceutical,nucleoside anti-virus

Zhejiang Che Tou Pharmaceutical Co., Ltd.

Home | 中文

中文版

News

Home page

Hotline:

E-mail:

Branch Link
- Jiangsu Baju Pharmaceutical Co., Ltd.
- Shanghai charette international trade co ltd

2011

Zhejiang Che Tou Pharmaceutical Co., Ltd. Founding Meeting and First General Meeting of Shareholders. The company officially changed its name to Zhejiang Chitou Pharmaceutical Co., Ltd.
The construction of the modern factory area of the parent company was officially launched;

2024

11-30

2008

The company has been identified as a national key high-tech enterprise and provincial post-doctoral research pilot unit;

2024

11-30

2004

The enterprise completed the restructuring and changed its name to "Zhejiang Che Tou Pharmaceutical Co., Ltd"
In March, it was identified as a high-tech enterprise in Zhejiang Province.
In May, naproxen and aciclovir products passed the European COS certification on-site inspection.
In July, naproxen sodium products through the United States FDA certification on-site inspection.
November through the integration certification program-ISO9000 site inspection,
December through the integration of certification project ISO14000, OHS18000 on-site inspection
In the same year, the wholly-owned subsidiaries of Jiangsu Baju Pharmaceutical Co., Ltd. and Shanghai Charrett International Trade Co., Ltd. were established;

2024

11-30

2003

The GMP inspection team of the National Bureau has passed the certification with high scores and high evaluation on the on-site inspection results of our company's products;

2024

11-30

1999

Renamed Zhejiang Xianju Che Tou Pharmaceutical Factory

2024

11-30

1996

Taizhou Zhiqing Chemical Co., Ltd., a wholly-owned subsidiary, was established.

2024

11-30

2024 Hazardous Waste Pollution Prevention and Control Information Disclosure

2024

12-05

Zhejiang Che Tou Pharmaceutical Co., Ltd. Environmental Emergency Plan and Emergency Plan Exercise Publicity

2024

12-05

"Zhejiang Chetou Pharmaceutical Co., Ltd. (Modern Factory) Annual Output of 500 Tons of D,L-Naproxen, 10 Tons of Imatinib Mesylate Production Line Construction Project Environmental Impact Report" (Public Draft) and "Public Participation Description"

2024

12-05

In July 2016, the company's naproxen products passed the MSDF inspection of the South Korea Food and Drug Administration.

2024

12-05

< 1 2 3 4 5 > proceed page

COOKIES

Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy

COOKIES

required

These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.

analyze

These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.

Feature

These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.

advertise

These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.

Business License

浙ICP备10002622号-38